Immunotherapy in Lung Cancer

The FDA granted an accelerated approval to pembrolizumab (Keytruda) for use in combination with pemetrexed plus carboplatin as a frontline treatment for patients with metastatic or advanced nonsquamous non-small cell lung cancer, regardless of PD-L1 expression. 
Read More >>
top border
top border
Featured Programs
Dr. Levy on Impact of Nivolumab, Pembrolizumab Approvals in NSCLC
Benjamin P. Levy, MD, assistant professor of Medicine, Hematology, and Medical Oncology at Mount Sinai Hospital, discusses how nivolumab (Opdivo) and pembrolizumab (Keytruda) have impacted the treatment landscape of non–small cell lung cancer (NSCLC). View Now

In this segment, Dean F. Bajorin, MD, and Evan Y. Yu, MD, discuss atezolizumab in muscle-invasive bladder cancer. View Now

 

Featured Video

Immune-Based Therapy for Urothelial Carcinoma

Immune-Based Therapy for Urothelial Carcinoma
A series of interviews focused on the treatment of metastatic urothelial carcinoma, including unmet needs, multidisciplinary care, and immunotherapy.
View Now

Gina Columbus

Gina Columbus reports on the latest news in oncology in this week's edition of OncLive News Network.

Publication Bottom Border
Border Publication